Aurora acquires 116,000 CanniMed shares
2018-01-02 18:45 ET - News Release
Mr. Terry Booth reports
AURORA PURCHASES 116,000 SHARES OF CANNIMED THERAPEUTICS INC.
Aurora Cannabis Inc. today purchased 116,000 common shares of CanniMed Therapeutics Inc.
The purchases were made in connection with Aurora's previously announced offer to purchase all of the common shares of CanniMed (the "Offer"). Aurora announced its intention to purchase common shares of CanniMed (the "CanniMed Shares") in its Offer to Purchase and Takeover Bid Circular dated November 24, 2017, which is filed on SEDAR under CanniMed's SEDAR profile. CanniMed implemented a shareholder rights plan on November 28, 2017, which prevented Aurora from commencing purchases in a timely fashion. The Ontario Securities Commission and the Saskatchewan Financial and Consumer Affairs Authority, in joint decisions dated December 22, 2017 and issued on December 27, 2017, cease traded the CanniMed rights plan.
The purchases were made by Aurora in the normal course through the facilities of the TSX.
Name of the Purchaser Aurora Cannabis Inc.
Number of CanniMed shares purchased on December 29, 2017 116,000
Highest price paid for the CanniMed shares on December 29, 2017 $24.00
Aggregate Number of CanniMed Shares Purchased through a published market since the Commencement of the Offer 566,000
Average price paid for the CanniMed shares purchased through a published market since the Commencement of the Offer $22.8287
Total Number of CanniMed Shares held by Aurora after the Purchase 566,000
How to Tender
Aurora encourages CanniMed shareholders to read the full details of the Offer set forth in the takeover bid circular and accompanying offer documents, (collectively, the "Offer Documents"), which contain detailed instructions on how CanniMed shareholders can tender their CanniMed common shares to the Offer. For assistance in depositing CanniMed common shares to the Offer, CanniMed shareholders should contact the depositary and the Information Agent for the Offer, Laurel Hill Advisory Group at Phone: 1-877-452-7184 (North American Toll Free Phone) and 1-416-304-0211 (Outside North America); Facsimile: 416-646-2415; and E-mail: assistance@laurelhill.com.
About the Offer
On November 24, 2017, Aurora formally commenced its Offer to purchase all of the issued and outstanding common shares of CanniMed for consideration consisting of common shares of Aurora. The Offer Document, including the takeover bid circular and related documents are available on SEDAR.
The Offer Documents are also available on Aurora's website at www.auroramj.com and shareholders are invited to visit cannimed.auroramj.com for further information.
Stock Options Issued
The Company granted 300,000 stock options to an officer of the Company exercisable at $9.60 per common share. The options shall vest quarterly over a period of 36 months and expire five years from the date of grant.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.